Zdravljenje koronavirusne bolezni 19 z zdravili
Overview of COVID-19 therapeutics

slovenian

2022

volume 73, issue 2

anti-inflammatory medications   antiviral medications   SARS-CoV-2

Slovensko farmacevtsko društvo
(Obvezni izvod spletne publikacije)

The underlying pathophysiologic evolution of the disease from the predominantly viral infection-driven phase to the late, immune-mediated phase is important in the assessment of the role of medications against COVID-19. The best results can be expected from the orally used nirmatrelvir coformulated with ritonavir, the intravenously used remdesivir and the anti-SARS-CoV-2 monoclonal antibodies. The oral antiviral molnupiravir is less effective. When treating the fully developed disease, the most widely tested medications are dexamethasone and tocilizumab. Other anti-inflammatory treatments, baricitinib, tofacitinib or anakinra, have been shown to express very good clinical endpoints, which were however proven in a single clinical trial. The virus mutating to a variant less likely to cause typical presentation with severe immunological derangements probably will prevent us from gaining further knowledge in this area of therapeutics.

29.08.2023